{"contentid": 487935, "importid": NaN, "name": "NICE approval for Olumiant, a new class of treatment for atopic eczema", "introduction": "People in England and Wales who are living with moderate to severe atopic dermatitis (also known as atopic eczema) now have a new treatment option routinely available on the National Health Service (NHS).", "content": "<p>People in England and Wales who are living with moderate to severe atopic dermatitis (also known as atopic eczema) now have a new treatment option routinely available on the National Health Service (NHS).&nbsp;&nbsp;</p>\n<p>Today, the UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has recommended US pharma major Eli Lilly&rsquo;s (NYSE: LLY) Olumiant (baricitinib) as an option for treating moderate to severe atopic dermatitis in adults if the disease has not responded to at least one systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine, and mycophenolate mofetil, or these are not suitable. As part of a confidential commercial agreement, the NHS will receive baricitinib at a discounted price.</p>\n<p>&ldquo;Lilly welcomes this decision from NICE which will give doctors and their patients a much-needed new treatment option. We know that people living with moderate to severe atopic dermatitis can find that the condition impacts much more than their skin,&rdquo; said Dr Jyun-Yan Yang, senior medical director Eli Lilly, Northern Europe. &ldquo;We are very pleased to be able to offer an innovative treatment for this group of patients, demonstrating Lilly&rsquo;s commitment to dermatology.&rdquo;</p>\n<p>Baricitinib acts on the immune system and blocks the action of JAK1 and JAK2, members of the JAK family of protein tyrosine kinases. These enzymes play an important role in the process of inflammation and inflammatory diseases like atopic dermatitis.</p>\n<p>As far back as June 2017, the NICE recommend Olumiant, developed in partnership with US biotech Incyte (Nasdaq: INCY), for some people with rheumatoid arthritis (RA).</p>", "date": "2021-03-03 15:53:00", "meta_title": "NICE approval for Olumiant, a new class of treatment for atopic eczema", "meta_keywords": "Eli Lilly, Olumiant, NICE, Approval, Eczema, Dermatitis, Atopic", "meta_description": "NICE approval for Olumiant, a new class of treatment for atopic eczema", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 15:53:09", "updated": "2021-03-03 15:59:46", "access": NaN, "url": "https://www.thepharmaletter.com/article/nice-approval-for-olumiant-a-new-class-of-treatment-for-atopic-eczema", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "nice-big-1.png", "image2id": "nice-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Dermatologicals", "topic_tag": "Focus On, Pricing, reimbursement and access", "geography_tag": "UK, USA", "company_tag": "Eli Lilly", "drug_tag": "Olumiant", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 15:53:00"}